Nuvation Bio (NUVB) to Post Quarterly Earnings on Thursday

Nuvation Bio (NYSE:NUVB) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.15) per share and revenue of $26.5250 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%.The business had revenue of $83.23 million for the quarter, compared to analysts’ expectations of $66.22 million. On average, analysts expect Nuvation Bio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Nuvation Bio Price Performance

Shares of Nuvation Bio stock opened at $6.58 on Thursday. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -15.30 and a beta of 1.52. The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15. The stock’s 50-day simple moving average is $5.53 and its 200-day simple moving average is $5.24. Nuvation Bio has a 52 week low of $2.18 and a 52 week high of $9.75.

Insider Transactions at Nuvation Bio

In other news, Director Robert Mashal acquired 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were acquired at an average cost of $4.73 per share, with a total value of $118,250.00. Following the acquisition, the director directly owned 225,000 shares of the company’s stock, valued at approximately $1,064,250. The trade was a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Philippe Sauvage sold 47,668 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $6.01, for a total value of $286,484.68. Following the transaction, the chief financial officer owned 12,673 shares of the company’s stock, valued at $76,164.73. This represents a 79.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 235,668 shares of company stock valued at $1,419,495 over the last 90 days. Insiders own 30.11% of the company’s stock.

Institutional Trading of Nuvation Bio

Hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its holdings in shares of Nuvation Bio by 852.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after acquiring an additional 2,424,109 shares during the last quarter. Armistice Capital LLC raised its position in Nuvation Bio by 359.2% during the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock valued at $8,495,000 after purchasing an additional 1,796,000 shares during the period. Millennium Management LLC raised its position in Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after purchasing an additional 1,298,131 shares during the period. SymBiosis Capital Partners LLC bought a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $11,200,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Nuvation Bio by 95.7% in the 3rd quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company’s stock worth $8,797,000 after purchasing an additional 1,162,837 shares during the period. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NUVB has been the topic of several recent analyst reports. HC Wainwright lifted their target price on Nuvation Bio from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Monday. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Nuvation Bio in a report on Wednesday, July 22nd. Zacks Research upgraded shares of Nuvation Bio from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Finally, Truist Financial upped their target price on shares of Nuvation Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nuvation Bio presently has an average rating of “Moderate Buy” and a consensus target price of $12.88.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.